View ValuationIkapharmindo Putramas 将来の成長Future 基準チェック /06現在、 Ikapharmindo Putramasの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Personal Products 収益成長15.2%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesReported Earnings • Apr 25First quarter 2026 earnings released: EPS: Rp0.52 (vs Rp0.84 loss in 1Q 2025)First quarter 2026 results: EPS: Rp0.52 (up from Rp0.84 loss in 1Q 2025). Revenue: Rp103.8b (up 15% from 1Q 2025). Net income: Rp877.4m (up Rp2.30b from 1Q 2025). Profit margin: 0.8% (up from net loss in 1Q 2025). The move to profitability was driven by higher revenue.お知らせ • Mar 28PT Ikapharmindo Putramas Tbk, Annual General Meeting, May 05, 2026PT Ikapharmindo Putramas Tbk, Annual General Meeting, May 05, 2026.Reported Earnings • Mar 19Full year 2025 earnings released: Rp17.09 loss per share (vs Rp2.98 profit in FY 2024)Full year 2025 results: Rp17.09 loss per share (down from Rp2.98 profit in FY 2024). Revenue: Rp363.6b (down 12% from FY 2024). Net loss: Rp28.8b (down Rp33.8b from profit in FY 2024).Reported Earnings • Nov 01Third quarter 2025 earnings released: Rp13.55 loss per share (vs Rp2.07 loss in 3Q 2024)Third quarter 2025 results: Rp13.55 loss per share (further deteriorated from Rp2.07 loss in 3Q 2024). Revenue: Rp81.7b (down 14% from 3Q 2024). Net loss: Rp22.8b (loss widened Rp19.3b from 3Q 2024).Board Change • Oct 14No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Independent Commissioner Susanto Lam was the last independent director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Mar 13PT Ikapharmindo Putramas Tbk, Annual General Meeting, Apr 24, 2025PT Ikapharmindo Putramas Tbk, Annual General Meeting, Apr 24, 2025.Reported Earnings • Jul 31Second quarter 2024 earnings releasedSecond quarter 2024 results: EPS: Rp0.82. Net income: Rp1.38b (up Rp1.38b from 2Q 2023).New Risk • May 19New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 2.3% Last year net profit margin: 4.0% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.3x net interest cover). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Profit margins are more than 30% lower than last year (2.3% net profit margin). Market cap is less than US$100m (Rp421.2b market cap, or US$26.5m).Reported Earnings • May 05Full year 2023 earnings releasedFull year 2023 results: Revenue: Rp441.1b (up 11% from FY 2022). Net income: Rp15.3b (down 7.5% from FY 2022). Profit margin: 3.5% (down from 4.2% in FY 2022). The decrease in margin was driven by higher expenses.Valuation Update With 7 Day Price Move • May 03Investor sentiment deteriorates as stock falls 27%After last week's 27% share price decline to Rp230, the stock trades at a trailing P/E ratio of 23.4x. Average trailing P/E is 24x in the Personal Products industry in Indonesia.Valuation Update With 7 Day Price Move • Mar 27Investor sentiment improves as stock rises 16%After last week's 16% share price gain to Rp312, the stock trades at a trailing P/E ratio of 31.7x. Average trailing P/E is 24x in the Personal Products industry in Indonesia.Valuation Update With 7 Day Price Move • Feb 15Investor sentiment improves as stock rises 19%After last week's 19% share price gain to Rp282, the stock trades at a trailing P/E ratio of 28.7x. Average trailing P/E is 24x in the Personal Products industry in Indonesia.New Risk • Jan 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indonesian stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.9x net interest cover). Minor Risks Share price has been volatile over the past 3 months (8.7% average weekly change). Market cap is less than US$100m (Rp370.6b market cap, or US$23.3m).Valuation Update With 7 Day Price Move • Jan 26Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to Rp220, the stock trades at a trailing P/E ratio of 22.4x. Average trailing P/E is 23x in the Personal Products industry in Indonesia.Valuation Update With 7 Day Price Move • Jan 09Investor sentiment improves as stock rises 24%After last week's 24% share price gain to Rp256, the stock trades at a trailing P/E ratio of 26x. Average trailing P/E is 23x in the Personal Products industry in Indonesia.お知らせ • Nov 08PT Ikapharmindo Putramas Tbk has completed an IPO in the amount of IDR 55.593863 billion.PT Ikapharmindo Putramas Tbk has completed an IPO in the amount of IDR 55.593863 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 336,932,500 Price\Range: IDR 165 Transaction Features: ESOP Related OfferingBoard Change • Nov 08No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Independent Commissioner Susanto Lam was the last independent director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Ikapharmindo Putramas は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測IDX:IKPM - アナリストの将来予測と過去の財務データ ( )IDR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/2026377,102-26,48830,08437,546N/A12/31/2025363,565-28,78522,55328,569N/A9/30/2025379,271-27,7604,66313,252N/A6/30/2025392,289-8,433-30,040-23,503N/A3/31/2025405,031671-32,846-29,782N/A12/31/2024412,0695,015-38,922-35,270N/A9/30/2024424,88911,934-58,516-53,173N/A6/30/2024424,3608,813-23,104-18,878N/A3/31/2024429,88710,092-29,935-22,645N/A12/31/2023441,13715,338-24,83220,350N/A12/31/2022398,73516,578-8,916-4,057N/A12/31/2021380,9178,12575,63078,463N/A12/31/2020715,8014,628-2,92914,575N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: IKPMの予測収益成長が 貯蓄率 ( 6.7% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: IKPMの収益がID市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: IKPMの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: IKPMの収益がID市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: IKPMの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: IKPMの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHousehold 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/21 20:54終値2026/07/21 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋PT Ikapharmindo Putramas Tbk 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • Apr 25First quarter 2026 earnings released: EPS: Rp0.52 (vs Rp0.84 loss in 1Q 2025)First quarter 2026 results: EPS: Rp0.52 (up from Rp0.84 loss in 1Q 2025). Revenue: Rp103.8b (up 15% from 1Q 2025). Net income: Rp877.4m (up Rp2.30b from 1Q 2025). Profit margin: 0.8% (up from net loss in 1Q 2025). The move to profitability was driven by higher revenue.
お知らせ • Mar 28PT Ikapharmindo Putramas Tbk, Annual General Meeting, May 05, 2026PT Ikapharmindo Putramas Tbk, Annual General Meeting, May 05, 2026.
Reported Earnings • Mar 19Full year 2025 earnings released: Rp17.09 loss per share (vs Rp2.98 profit in FY 2024)Full year 2025 results: Rp17.09 loss per share (down from Rp2.98 profit in FY 2024). Revenue: Rp363.6b (down 12% from FY 2024). Net loss: Rp28.8b (down Rp33.8b from profit in FY 2024).
Reported Earnings • Nov 01Third quarter 2025 earnings released: Rp13.55 loss per share (vs Rp2.07 loss in 3Q 2024)Third quarter 2025 results: Rp13.55 loss per share (further deteriorated from Rp2.07 loss in 3Q 2024). Revenue: Rp81.7b (down 14% from 3Q 2024). Net loss: Rp22.8b (loss widened Rp19.3b from 3Q 2024).
Board Change • Oct 14No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Independent Commissioner Susanto Lam was the last independent director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Mar 13PT Ikapharmindo Putramas Tbk, Annual General Meeting, Apr 24, 2025PT Ikapharmindo Putramas Tbk, Annual General Meeting, Apr 24, 2025.
Reported Earnings • Jul 31Second quarter 2024 earnings releasedSecond quarter 2024 results: EPS: Rp0.82. Net income: Rp1.38b (up Rp1.38b from 2Q 2023).
New Risk • May 19New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 2.3% Last year net profit margin: 4.0% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.3x net interest cover). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Profit margins are more than 30% lower than last year (2.3% net profit margin). Market cap is less than US$100m (Rp421.2b market cap, or US$26.5m).
Reported Earnings • May 05Full year 2023 earnings releasedFull year 2023 results: Revenue: Rp441.1b (up 11% from FY 2022). Net income: Rp15.3b (down 7.5% from FY 2022). Profit margin: 3.5% (down from 4.2% in FY 2022). The decrease in margin was driven by higher expenses.
Valuation Update With 7 Day Price Move • May 03Investor sentiment deteriorates as stock falls 27%After last week's 27% share price decline to Rp230, the stock trades at a trailing P/E ratio of 23.4x. Average trailing P/E is 24x in the Personal Products industry in Indonesia.
Valuation Update With 7 Day Price Move • Mar 27Investor sentiment improves as stock rises 16%After last week's 16% share price gain to Rp312, the stock trades at a trailing P/E ratio of 31.7x. Average trailing P/E is 24x in the Personal Products industry in Indonesia.
Valuation Update With 7 Day Price Move • Feb 15Investor sentiment improves as stock rises 19%After last week's 19% share price gain to Rp282, the stock trades at a trailing P/E ratio of 28.7x. Average trailing P/E is 24x in the Personal Products industry in Indonesia.
New Risk • Jan 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indonesian stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.9x net interest cover). Minor Risks Share price has been volatile over the past 3 months (8.7% average weekly change). Market cap is less than US$100m (Rp370.6b market cap, or US$23.3m).
Valuation Update With 7 Day Price Move • Jan 26Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to Rp220, the stock trades at a trailing P/E ratio of 22.4x. Average trailing P/E is 23x in the Personal Products industry in Indonesia.
Valuation Update With 7 Day Price Move • Jan 09Investor sentiment improves as stock rises 24%After last week's 24% share price gain to Rp256, the stock trades at a trailing P/E ratio of 26x. Average trailing P/E is 23x in the Personal Products industry in Indonesia.
お知らせ • Nov 08PT Ikapharmindo Putramas Tbk has completed an IPO in the amount of IDR 55.593863 billion.PT Ikapharmindo Putramas Tbk has completed an IPO in the amount of IDR 55.593863 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 336,932,500 Price\Range: IDR 165 Transaction Features: ESOP Related Offering
Board Change • Nov 08No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Independent Commissioner Susanto Lam was the last independent director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.